Antibiotic Side Effects Linked to Aortic Aneurysm, Dissection Risk in Mice: Study

A new study warns that the side effects of antibiotics like Cipro, Levaquin and Avelox may increase the risk of aortic aneurysms and aortic dissections; which are potentially deadly tears and ruptures in the aorta. 

The research was presented at the American Heart Association Scientific Sessions on November 17, indicating that testing on mice provides insight into the link between use of the popular antibiotics and aortic injuries.

Researchers from Baylor’s College of Medicine conducted tests on mice with normal or moderately stressed aortas, giving them either Cipro (ciproflaxin) or a placebo. Cipro belongs to a class of popular antibiotics known as fluoroquinolones, which also includes the widely used brand-name drugs Levaquin and Avelox.

Sports-Betting-Addiction-Lawsuits
Sports-Betting-Addiction-Lawsuits

The study found that mice with unstressed aortas appeared to be unaffected. However, 79% of mice with moderately stressed aortas developed aortic aneurysms or dissections, with 67% developing the more serious aortic dissections and 15% suffering fatal ruptures. Among those given a placebo, only 45% of those with stressed aortas were diagnosed with aortic aneurysm or dissection, with 25% developing dissections and none suffering ruptures.

According to the researchers’ findings, Cipro appeared to decrease the activity of an enzyme known as LOX, which helps stabilize the extracellular matrix. It also increased enzymes that led to extracelluar matrix degeneration and cell death.

Aortic aneurysm is a painful and potentially serious condition involving a bulge in the aorta, where the walls of the artery have weakened. They can cause severe chest pain, as well as carry the risk of rupturing. Aortic dissections are similar, but potentially more serious and life-threatening condition, involving degradation within the layers of the aorta. Both pose a serious health risk and usually require invasive surgery to treat.

In October 2015, a report published in the medical journal JAMA Internal Medicine found that current use of Levaquin, Avelox or other similar fluoroquinolone antibiotics was associated with a two-fold increased risk of suffering an aortic aneurysm or dissection injury. The research was conducted to examine whether the known risk of collagen degredation from fluoroquinolones, which causes the risk of tendon ruptures, may also cause problems with the aorta.

The FDA issued a major fluoroquinolone antibiotics warning on May 12, 2016, indicating that a variety of “disabling and potentially serious side effects” led the agency to conclude that the risks may outweigh the benefits associated with using the medications to treat uncomplicated infections.

That warning concerned reports of permanent nerve damage, known as peripheral neuropathy, as well as tendon ruptures and other health risks. However, the statement did not address concerns about the risk of aortic aneurysm and aortic dissection from the antibiotics, which emerged with the publication of an independent study months earlier.

In May 2017, the FDA issued another drug safety communication indicating that it found no link between Cipro and similar antibiotics and an increased risk of aortic aneurysm and aortic dissection. However, this latest study seems to provide some additional information about the potential link and biological mechanism.

There are currently hundreds of Levaquin lawsuitsAvelox lawsuits and Cipro lawsuits filed throughout the federal court system over side effects allegedly caused by the antibiotics, and a number of lawyers have also been investigating potential cases over the past two years for individuals diagnosed with an aortic aneurysm or dissection injury.

Written by: Irvin Jackson

Senior Legal Journalist & Contributing Editor

Irvin Jackson is a senior investigative reporter at AboutLawsuits.com with more than 30 years of experience covering mass tort litigation, environmental policy, and consumer safety. He previously served as Associate Editor at Inside the EPA and contributes original reporting on product liability lawsuits, regulatory failures, and nationwide litigation trends.




0 Comments


This field is for validation purposes and should be left unchanged.

Share Your Comments

This field is hidden when viewing the form
I authorize the above comments be posted on this page
Post Comment
Weekly Digest Opt-In

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

MORE TOP STORIES

Dupixent users are coming forward with accounts of devastating cancer diagnoses, saying the popular eczema drug masked early warning signs of cutaneous T-cell lymphoma. As the FDA investigates and the first lawsuit is filed, researchers warn Dupixent may unmask or accelerate hidden cancers, raising urgent questions about its long-term safety.
Plaintiffs involved in GLP-1 vision loss lawsuits are calling for the litigation to be consolidated in New Jersey federal court, and not be bundled with existing stomach paralysis litigation.